NASDAQ:GDRX

GoodRx Q3 2026 Earnings Date & Estimates

GoodRx logo
$2.92 -0.10 (-3.31%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.86 -0.06 (-1.99%)
As of 11/20/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GoodRx is estimated to report Q3 2026 earnings on Monday, November 23, 2026, after market closes. The conference call is scheduled for November 25, 2026 at 8:00 AM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET

What Analysts Expect from GoodRx in Q3 2026

GoodRx is expected to post earnings of $0.0742 per share on revenue of $203.33 million. In the same quarter a year earlier GoodRx reported $0.08 per share on revenue of $196.03 million. GoodRx last reported on August 5, 2026, posting $0.08 per share and beating the $0.0797 consensus estimate. GoodRx has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.0742
Expected Revenue
$203.33 million
Prior-Year EPS
$0.08
Prior-Year Revenue
$196.03 million
Expected EPS Growth
-7.3%
Expected Revenue Growth
+3.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.08 (Beat by +$0.0003)
Last Quarter Revenue
$200.41 million
EPS Beat Rate
2 of last 8 quarters

GoodRx Q3 2026 Earnings FAQ

GoodRx (NASDAQ:GDRX) is estimated to report Q3 2026 earnings on Monday, November 23, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

GoodRx's Q3 2026 earnings conference call is scheduled for Wednesday, November 25, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect GoodRx to post earnings of $0.0742 per share for Q3 2026.

The consensus revenue estimate for GoodRx is $203.33 million for Q3 2026.

GoodRx Earnings Headlines

Financial Contrast: GoodRx (GDRX) & Its Rivals
GoodRx stock rises on Google Cloud healthcare AI partnership
“IMPERIUM”: The #1 investment of 2027
Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A NASA scientist says it's "bigger than AI." A Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money & Markets, calls the technology Imperium. He says it's set to spark a major investment megatrend, with one small Silicon Valley company at the center.tc pixel
See More GoodRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GoodRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GoodRx and other key companies, straight to your email.

About GoodRx

GoodRx (NASDAQ:GDRX) operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions.

The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.

Founded in 2011, GoodRx is based in Santa Monica, California. The company’s business focuses on the U.S. healthcare market.

View GoodRx Profile